Press Releases

Sep 9, 2026

Caleb Monroe

Press Releases

Lightbridge Secures Access to Idaho National Laboratory's Advanced Test Reactor Loop Facility to Irradiate Clad Lightbridge Fuel™ Rodlets Under Prototypic Commercial Reactor Conditions

Lightbridge Corporation has secured access to the Advanced Test Reactor (ATR) loop testing facility at Idaho National Laboratory to irradiate its Lightbridge Fuel™ rodlets under commercial reactor conditions. This milestone enables critical data collection for fuel performance validation and supports progression toward fuel qualification and commer…

LTBR

Sep 9, 2026

Leila Farooq

Press Releases

Destination XL Group, Inc. Reports Second Quarter Financial Results

Destination XL Group, Inc., a leading Big + Tall men's apparel retailer, reported Q2 FY2026 sales of $111.6 million, a 3.4% decline from the prior year, with comparable sales down 3.5%. Despite sales pressure and ongoing economic headwinds, net income improved to $2.0 million aided by a $4.6 million tariff refund. The company is focusing on strateg…

DXLG

Sep 9, 2026

Marcus Reed

Press Releases

SailPoint Announces Fiscal Second Quarter 2027 Results

SailPoint, Inc., a leader in enterprise identity security, announced its financial results for the fiscal second quarter ended July 31, 2026, and hosted a conference call to discuss its performance and outlook. The company emphasizes its role in securing digital and human identities for modern enterprises through its identity-first security platfor…

SAIL

Sep 9, 2026

Sofia Navarro

Press Releases

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR

Fate Therapeutics announced the presentation of clinical and pre-clinical data for its off-the-shelf CAR T-cell therapies FT819 and FT839 at the Congress of Clinical Rheumatology West meeting. The Phase 1 trial data for FT819 demonstrates favorable safety, early and sustained efficacy in systemic lupus erythematosus (SLE) patients, supporting advan…

FATE

Sep 9, 2026

Leila Farooq

Press Releases

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm Theranostics announced positive Phase 1 trial results for RAD301, a novel Gallium-68 labeled peptide targeting αvβ6-integrin in pancreatic ductal adenocarcinoma (PDAC) patients. The trial demonstrated favorable safety, significant tumor uptake, and selective biodistribution, indicating RAD301’s potential to improve pancreatic cancer imag…

RADX

Sep 9, 2026

Ajmal Hussain

Press Releases

Balchem Corporation to Participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026

Balchem Corporation, a global specialty ingredient manufacturer serving health and nutrition markets, announced its participation in the 9th Annual Wells Fargo Consumer Conference. Senior executives including the CEO, CFO, and Senior Director of Investor Relations will present, highlighting the company's multi-segment operations across human nutrit…

BCPC

Sep 9, 2026

Avery Klein

Press Releases

Fractyl Health to Participate in Upcoming September Investor Conferences

Fractyl Health, a clinical-stage metabolic therapeutics company targeting obesity and type 2 diabetes, announced CEO Dr. Harith Rajagopalan will present and engage in meetings at the H.C. Wainwright and Morgan Stanley healthcare investment conferences in September 2026. The events will be webcast and focus on the company’s advanced metabolic diseas…

GUTS

Sep 9, 2026

Avery Klein

Press Releases

ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter

ODDITY Tech Ltd. reported Q2 2026 net revenue of $181 million, down 25% year-over-year, with adjusted EBITDA of $13 million and net income of $13 million. The company highlighted strong revenue growth in its SpoiledChild brand and promising early results from METHODIQ. It is addressing a technical advertising issue with its largest partner affectin…

ODD

Sep 9, 2026

Avery Klein

Press Releases

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals, a US-based biotech firm focused on rare hematology diseases, will take part in a management fireside chat at the 2026 Wells Fargo Healthcare Conference. The company is developing and commercializing mavorixafor, an oral CXCR4 antagonist currently approved in the US and undergoing pivotal Phase 3 trials for chronic neutropenia. T…

XFOR

Sep 9, 2026

Avery Klein

Press Releases

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Autolus Therapeutics announced that the FDA granted RMAT designation to its T cell therapy candidate obecabtagene autoleucel (obe-cel) for treating systemic lupus erythematosus (SLE) and lupus nephritis (LN), accelerating development and regulatory review. The company plans further clinical data presentations and continues enrollment in a pivotal P…

AUTL

Sep 9, 2026

Hana Yamamoto

Press Releases

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Pyxis Oncology reported positive updated results from its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The study showed a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months,…

PYXS

Sep 9, 2026

Leila Farooq

Press Releases

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute announced that the FDA review of their Phase 3 sunRIZE study data for their drug ersodetug in treating congenital hyperinsulinism (HI) is ongoing without a defined timeline. While the study did not meet its primary endpoint for statistical significance, secondary analyses indicate glycemic improvements. The open-label extension phase conti…

RZLT

Sep 9, 2026

Leila Farooq

Press Releases

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Kura Oncology has established Caspian Therapeutics, a separately financed subsidiary focused on advancing KO-7246, a next-generation menin inhibitor designed for diabetes and cardiometabolic diseases. Caspian raised $50 million led by BVF Partners and supported by key biotech investors including Eli Lilly. Preclinical studies show promising results…

KURA

Sep 9, 2026

Marcus Reed

Press Releases

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Satellos Bioscience announced that their lead oral small molecule drug candidate, previously known as SAT-3247, has been assigned the International Nonproprietary Name (INN) 'forazapadin.' The drug targets AAK1 to promote muscle regeneration and is currently in Phase 2 clinical trials for Duchenne muscular dystrophy (DMD), with plans to initiate a …

MSLE

Sep 9, 2026

Derek Hwang

Press Releases

Aya Gold & Silver Announces Updated PEA for Boumadine: After-Tax NPV Doubles to $3.5B with 93% IRR

Aya Gold & Silver released an updated 2026 Preliminary Economic Assessment for its Boumadine polymetallic project in Morocco, showing a more than doubling of the after-tax net present value to $3.5 billion and an internal rate of return of 93%. The project life extends to 14 years with improved payable metal production and capital efficiency. The u…

AYA

Sep 9, 2026

Sofia Navarro

Press Releases

INLIF LIMITED Announces Adjournment of Extraordinary General Meeting

INLIF LIMITED announced that its Extraordinary General Meeting of Shareholders originally scheduled for September 8, 2026, was adjourned due to insufficient shareholder attendance to meet quorum requirements. The meeting is set to reconvene on September 15, 2026. Previously submitted votes remain valid, and shareholders who have not yet voted are e…

INLF

Sep 9, 2026

Derek Hwang

Press Releases

Xanadu and ASML Announce Collaboration to Advance Lithography for Photonic Quantum Hardware

Xanadu Quantum Technologies Limited has entered into a collaboration with ASML to develop advanced lithography techniques aimed at reducing optical losses in photonic quantum computing chips. This partnership seeks to address critical challenges in achieving fault-tolerant and error-corrected quantum hardware, accelerating progress toward utility-s…

XNDU

Sep 9, 2026

Avery Klein

Press Releases

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon Pharmaceuticals announced an upcoming oral presentation at the International Congress of The Transplantation Society showcasing long-term safety and efficacy data of its lead investigational drug, tegoprubart, for preventing kidney transplant rejection. The data come from the Phase 2 BESTOW trial and its extension, highlighting the drug's po…

ELDN

Sep 9, 2026

Avery Klein

Press Releases

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections. This study is the first clinical trial of a direct-acting antiviral specifically targeting norovirus, aiming to address a significant unmet medical need. CDI-988 has sho…

COCP

Sep 9, 2026

Nina Shah

Press Releases

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma Limited announced presentations at the Ophthalmology Futures European Forum and ESCRS iNovation Day, highlighting the advancement of its lead drug urcosimod in treating neuropathic corneal pain. The company also reported positive feedback from the FDA validating its regulatory pathway and a strengthened cash position, supporting the upc…

OKYO

Sep 9, 2026

Maya Rios

Press Releases

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite BioPharma announced publication of a peer-reviewed case report detailing the successful treatment of a patient with advanced decompensated liver cirrhosis using their drug Namodenoson, resulting in resolution of ascites and regression of esophageal varices. The patient remained clinically stable for 28 months on treatment before undergoing…

CANF

Sep 9, 2026

Sofia Navarro

Press Releases

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

Telix Pharmaceuticals Limited announced that its senior executives will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company, a global radiopharmaceutical leader in cancer theranostics, aims to showcase its commercial progress and future plans to investo…

TLX

Sep 9, 2026

Marcus Reed

Press Releases

Einride Expands Defense Offering With Mission Planning and Operational Decision-Making for Autonomous Logistics

Einride AB announced a strategic partnership with UNIQAI Systems to enhance its autonomous logistics platform with AI-driven mission planning and operational decision-making capabilities tailored for defense and national security clients. Building on its existing autonomous freight technology and previous collaborations, Einride aims to address a s…

ENRD

Sep 9, 2026

Nina Shah

Press Releases

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MannKind Corporation has entered into a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, a rapid-acting, short-duration inhaled GLP-1 receptor agonist for weight management. MannKind will provide pharmaceutical development and manufacturing support through Phase 1b trials, receive equity in Rose Pharma, …

MNKD

Sep 9, 2026

Marcus Reed

Press Releases

Sysco Reaffirming Fiscal 2027 Guidance; Introducing $500 Million Multi-Year AI Powered Efficiency Program; Raising Mid-Term Financial Algorithm Targets

Sysco Corporation reaffirmed its fiscal 2027 financial guidance with expected adjusted EPS growth of 9%-11% and announced a new $500 million multiyear AI-powered efficiency program aimed to reduce structural costs by fiscal 2029. The company also raised its mid-term financial targets for net sales and adjusted EPS growth for fiscal years 2028 and 2…

SYY